Focusing attention on cardiovascular diseases, international guidelines and studies conducted on large populations suggest that, beyond its limited use on diagnosis of HF respect other biomarkers (i.e., pro-BNP, hs-CRP, and hs-TnT), the evaluation of sST2 is extremely useful in correlation to clinical data, in particular on the severity of the underlying cardiomyopathy, left ventricle hypertrophy, cardiac remodeling, ejection fraction, NYHA score, and finally to obtain prognostic information, especially regarding medium- to long-term mortality. The gene discussed is NPPB; the disease is cardiomyopathy.